Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction

  • Technology appraisal guidance
  • TA73
  • Published: 
  • Last updated: 
Download guidance (PDF)

Appendix B. Sources of evidence considered by the Committee

The following documentation and opinions were made available to the Committee:

A The Assessment Report for this appraisal was prepared by the Health Services Research Unit in collaboration with the Health Economics Research Unit, the Department of Public Health, Institute of Applied Health Sciences, and the Cardiology Research Group, University of Aberdeen, and the Department of Bio-Medical Physics and Bio-Engineering, Grampian University Hospitals NHS Trust.

Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction

Graham Mowatt, Luke Vale, Miriam Brazzelli, Rodolfo Hernandez, Alison Murray, Neil Scott, Cynthia Fraser, Lynda McKenzie, Howard Gemmell, Graham Hillis, and Malcolm Metcalfe, May 2003.

B The following organisations accepted the invitation to participate in this appraisal. They were invited to make submissions and comment on the draft scope, assessment report and the Appraisal Consultation Document (ACD). Consultee organisations are provided with the opportunity to appeal against the Final Appraisal Determination.

I Manufacturer/sponsors:

  • Amersham Health

  • Ashby GB Ltd

  • Bartec Medical Systems (UK) Ltd

  • Bristol-Myers Squibb

  • GE Medical Systems

  • Philips Medical Systems

  • Siemens

  • Tyco Healthcare UK Ltd

II Professional/specialist and patient/carer groups:

  • Action Heart

  • Association of British Health-Care Industries

  • British Cardiac Patients Association

  • British Cardiac Society

  • British Cardiovascular Interventional Society

  • British Heart Foundation

  • British Nuclear Cardiology Society

  • British Nuclear Medicine Society

  • Department of Health

  • Fareham and Gosport Primary Care Trust

  • Maidstone Weald Primary Care Trust

  • Royal College of Physicians

  • Royal College of Radiologists

  • Society for Cardiological Science and Technology

  • Welsh Assembly Government

III Commentator organisations (without the right of appeal):

  • Cochrane Heart Group

  • Institute of Nuclear Medicine

  • Institute of Physics and Engineering in Medicine

  • NHS Confederation

  • NHS Information Authority

  • NHS Purchasing and Supply Agency

  • NHS Quality Improvement Scotland

C The following individuals were selected from clinical expert and patient advocate nominations from the professional/specialist and patient/carer groups. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Constantinos Anagnostopoulos, President, British Nuclear Cardiology Society and Consultant & Honorary Senior Lecturer of Nuclear Medicine, Department of Nuclear Medicine, Royal Brompton Hospital, London

  • Professor SR Underwood, Professor of Cardiac Imaging, Royal Brompton Hospital, London